Today: 22 November 2025
Subscribe
Browse Category

Pharmaceuticals News 17 October 2025 - 23 October 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Stock Performance and Recent Moves Eli Lilly (NYSE: LLY) has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1 ts2.tech ts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rally ts2.tech. By Oct. 23, LLY was trading
23 October 2025
 ·  ·  ·  ·  · 
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

SCNX Stock Soars on Arbli Launch News Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers – making it the first FDA-approved liquid losartan on the market ts2.tech. That morning, SCNX shares surged over 30% from the prior day’s $0.72 close, even hitting an intraday high around $1.12 before profit-taking set in ts2.tech. By mid-day Oct. 16, Reuters reported the stock had pulled back near $0.71 ts2.tech, indicating traders sold into the early pop. Still, the
23 October 2025
 ·  ·  ·  · 
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes Buyout Sparks Rally in AVDL Stock On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right (CVR) tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have
22 October 2025
 ·  ·  ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com. Trading reacted sharply. Novo’s Copenhagen-listed shares briefly plunged 6% on Oct. 17 when President Trump
22 October 2025
 ·  ·  ·  ·  · 
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the news gurufocus.com. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97 marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past year marketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this
21 October 2025
 ·  ·  ·  · 
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s close marketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-date marketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech
21 October 2025
 ·  ·  ·  · 
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average (~$2.03) and 200-day average (~$1.83) (see data marketbeat.com) suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average. Recent Developments gsk.com gsk.com At IDWeek
21 October 2025
 ·  ·  ·  ·  ·  · 
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Stock Soars on Oct 20 Amid Wild October Trading Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8 benzinga.com. The rally comes after shares slid 7.9% on Friday to $5.86 stockinvest.us, as traders took profits following a mid-October run-up. Broader market tailwinds helped – the Nasdaq Composite was up ~1% on Monday – and several biotech peers also soared on news (for example, Replimune jumped 100%+ on an FDA decision, and Celcuity climbed 46% on trial data) benzinga.com. Recursion’s sharp rebound Monday recoups some losses from last week’s
20 October 2025
 ·  ·  ·  · 
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range. The catalyst was clear: on Sept. 30 Trump’s administration announced the Pfizer pricing deal, and PFE instantly rallied. Shares jumped about 6–7% on
19 October 2025
 ·  ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains (the S&P 500 and Nasdaq Composite were each up only ~0.5% that day investing.com). Deal Details: Under the Chugai
18 October 2025
 ·  ·  ·  ·  · 
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 stockanalysis.com stockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47% ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same period ts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects
18 October 2025
 ·  ·  ·  ·  · 
XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Stock Price Skyrockets on Acquisition News Shares of XORTX Therapeutics Inc. (NASDAQ: XRTX) surged on October 17, 2025 after the nano-cap biotech announced a strategic acquisition in its core therapeutic area. The stock rocketed up immediately following the morning press release, spiking up to 40% in early trading. By midday, XRTX was changing hands at just over $1.20 per share (up from around $0.86 the prior day) ragingbull.com. It eventually closed about 21% higher on Friday tipranks.com – a dramatic move for a company that had been trading quietly near the $1 level. This rally was accompanied by an
17 October 2025
 ·  ·  ·  ·  · 
1 … 5 6 7 8 9 10
Go toTop